

# Oregon Prescription Drug Monitoring Program 2021 1st Quarter Report


Percentage change evaluated relative to 1st Quarter, 2020

[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



## Summary

- Registration has increased over the last year for several user groups (MD/PA/DO, +3.6%; NP, +0.3%) but decreased for all others (Table 4). Overall, there were 31,750 registered users in the first quarter of 2020 compared to 31,487 users in the current quarter, a 0.8% decrease. The change is likely due to removal of inactive user accounts, which occurred in the first quarter of 2021.
- Integrated queries have increased 27.4% while web queries have decreased by 9.8% from the 1st quarter of 2020 (Table 1).
- The percentage of prescribers who queried the PDMP is up 35% compared to the first quarter of 2020 (Table 3). This may be driven by the 31.3% increase seen for integrated queries (Table 1).
- Overall, prescriptions of controlled substances are down 3.4%, while amphetamine prescriptions are up 9.9% (Table 5).
- 23.8% of opioid prescribers this quarter were responsible for at least one prescription of over 90 morphine milligram equivalents (newly calculated metric).<sup>#</sup>



<sup>#</sup> Revised on 2021-12-14 from an earlier report.

(Note: Report formatting updated August 2022. No major content changes.)

Oregon Prescription Drug Monitoring Program  
2021 1st Quarter Report

Percentage change evaluated relative to 1st Quarter, 2020

healthoregon.org/pdmp



**Table 1. PDMP Queries Summary Statistics: January-March, 2021**

Measure	Web Portal	% Change*	Integrated	% Change*
<b>Queries †</b>	288,752	- 9.8 %	6,984,428	+ 27.4%
<b>Healthcare providers</b>	80,520	- 1.5%	5,982,142	+ 31.3%
<b>Pharmacies</b>	57,702	- 29.9%	1,002,286	+ 8.4%
<b>Delegates</b>	150,445	- 3.5%	-	-

- Web Portal queries have decreased from the same quarter last year across all user groups.
- Integrated Query data indicates that the number of integrated queries from healthcare providers and pharmacists has increased over the same quarter last year. But the percent increase is smaller than recent quarters (e.g., 2019 3rd quarter—2020 3rd quarter).
- Patterns of PDMP use are likely driven by the increasing adoption of PDMP integration by hospitals, clinics and pharmacies.

**Table 2. Special Requests: January-March, 2021**

Measure	Count
<b>Special Requests Total</b>	84
<b>Patient Records</b>	11
<b>Healthcare Board</b>	67
<b>Law Enforcement</b>	6

- 84 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.
- The decrease in requests may be a consequence of COVID-19.

\* Percentage change figures evaluated relative to the same time period during the prior year.

† Query data drawn from Appriss AWARe web portal, the PMPi Gateway audit file and the EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

(Note: Report formatting updated August 2022. No major content changes.)

Oregon Prescription Drug Monitoring Program  
2021 1st Quarter Report

Percentage change evaluated relative to 1st Quarter, 2020

healthoregon.org/pdmp



**Table 3. PDMP Enrollment and System Use: January-March, 2021**

	Prescribers	Enrolled	Web Queried	Integrated	Total Queried
<b>All Prescribers (by DEA)*</b>	18,310	15,473 / 84.5 %	5,989 / 36.1 %	11,391 / 73.6 %	12,682 / 82.0 %
<b>Top 4K Prescribers</b>	4,000	3,858 / 96.5 %	2,295 / 59.5 %	3,413 / 88.5 %	3,664 / 95.0 %
<b>Top 2K Prescribers</b>	2,000	1,957 / 97.9 %	1,264 / 64.6 %	1,762 / 90.0 %	1,869 / 95.5 %

- During the 1st quarter of 2021 there were 18,310 prescribers who wrote prescriptions for controlled substances in Oregon.
- At the close of the 1st quarter, 82 % of enrolled prescribers queried the system; 95 % of the top 4,000 prescribers; 95.5 % of the top 2,000 prescribers through the web portal or integration.
- The percentage of enrolled prescribers who queried the system has increased 35 % since the first quarter of 2020, when 60.7 % of enrolled prescribers submitted queries.

**Table 4. PDMP Query by Clinical User Group: January-March, 2021**

Discipline	Total User Accounts (by DEA)*	% Change*	Web Users±†	% Change*	Integrated Users	% Change*
MD/PA/DO	17,528	+ 3.6 %	1,812	- 16.1 %	12,672	+ 5.3 %
NP/CNS-PP	4,015	+ 0.3 %	976	- 5.7 %	2,897	+ 6.5 %
RPh	3,305	- 10.5 %	1,508	- 12.2 %	342	+ 64.4 %
Delegates	3,341	- 16.4 %	1,937	- 16.2 %	-	-
DDS/DMD	2,736	- 4.4 %	406	- 9.8 %	226	+ 4.1 %
ND	562	- 2.9 %	145	- 7.1 %	399	+ 2.3 %

- Patterns of registration are likely driven by state mandated PDMP registration for prescribers and HIT integration efforts undertaken by health care systems.
- The number of users accessing the PDMP through the web portal is decreasing, while integrated users are increasing.

\* Prescriber counts provided by unique DEA Number. Please note some providers may be associated with multiple DEA numbers.

\* Percentage change figures evaluated relative to the same time period during the prior year.

± Users that have submitted a query this quarter.

† Query data drawn from Appriss AWAxR and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

(Note: Report formatting updated August 2022. No major content changes.)

**Table 5. Top Prescriptions: January-March, 2021**

Drug	# of Rx	% of all Rx	% Change*
All	1,638,180	100.0 %	- 3.4 %
Hydrocodone	238,079	14.5 %	-4.9 %
Gabapentin	223,553	13.6 %	+ 1.4 %
Oxycodone	222,162	13.6 %	+ 2.2 %
Amphetamine	159,436	9.7 %	+ 9.9 %
Lorazepam	83,992	5.1 %	- 3.2 %
Tramadol	80,947	4.9 %	- 4.6 %
Methylphenidate	71,066	4.3 %	- 5.2 %
Zolpidem	66,610	4.1 %	- 8.8 %
Alprazolam	61,503	3.8 %	- 9.6 %
Clonazepam	59,793	3.6 %	- 6.1 %

- The number of prescriptions for oxycodone increased relative to the same quarter last year, while hydrocodone decreased.
- The number of prescriptions for commonly prescribed benzodiazepines decreased (i.e., lorazepam, alprazolam, clonazepam).
- Prescriptions for amphetamine increased relative to the same quarter last year.
- Prescriptions for gabapentin increased, reflecting compliance with the addition of this drug as a PDMP covered substance, effective January 1st, 2020. This addition also contributed to an overall increase in the number of prescriptions in the PDMP.

**Table 6. Prescriptions for Buprenorphine and Naloxone: January-March, 2021**

Drug	# of Rx	% of all Rx	% Change*
Buprenorphine	38,329	2.3 %	+ 7.8 %
Buprenorphine/Naloxone	20,624	1.3 %	- 23.4 %
Naloxone	5,093	0.3 %	+ 19.2 %

- Prescriptions for buprenorphine and naloxone have increased while prescriptions for buprenorphine/naloxone combinations have decreased relative to the same quarter last year.

**Contact: PDMP Research Analyst, [pdmp.research@state.or.us](mailto:pdmp.research@state.or.us)**

\* Percentage change figures evaluated relative to the same time period during the prior year.  
(Note: Report formatting updated August 2022. No major content changes.)